An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-Cell Function
Authors:
- Irene M. MinIMIrene M. Min
- Yanping YangYYYanping Yang
- Dessislava StefanovaDSDessislava Stefanova
- Yogindra VedvyasYVYogindra Vedvyas
- Diella S. BabuDBDiella S. Babu
- Dong-Hyun LeeDLDong-Hyun Lee
- Yago AlcainaYAYago Alcaina
- Maria Cristina RiascosMRMaria Cristina Riascos
- Janusz PucJPJanusz Puc
- Kevin J. ChenKCKevin J. Chen
- Juan Gonzalez-ValdiviesoJuan Gonzalez-Valdivieso
- Jose ThaiparambilJTJose Thaiparambil
- 8 June 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (7) , OF1-OF17
Abstract
Engineered T-cell therapies, such as chimeric antigen receptor (CAR)– and T-cell receptor (TCR)–based approaches, have transformed outcomes in hematologic malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or TCR signaling. To overcome these barriers, we developed an intercellular adhesion molecule 1 (ICAM1)–specific chimeric costimulatory receptor (ICCR) engineered for expression in T cells to augment their activation. ICAM1 is broadly expressed across solid tumors and is further upregulated by IFNγ released during early T-cell engagement, creating a feed-forward loop that reinforces tumor recognition. ICCR engagement with ICAM1 triggered NF-κB signaling independently of TCR–peptide (p)/MHC engagement; however, full T-cell activation and cytotoxic function remained dependent on intact TCR signaling. In primary T cells, ICCR increased proliferation, cytokine production, and cytotoxicity, resulting in improved tumor control in two anaplastic thyroid cancer xenograft models treated with allogeneic or autologous ICCR-T cells. Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse–mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T-cell responses in solid tumor microenvironments.Keywords
Funding Information
- National Cancer Institute (R21 CA280566)
- National Cancer Institute (R01CA254035)
- National Cancer Institute (R01CA254035)
- Emerson Collective (COR9)
This publication has 48 references indexed in Scilit:
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary SignalingJournal of Clinical Immunology, 2012
- TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune TargetsJournal of Immunology Research, 2012
- Strength of TCR–Peptide/MHC Interactions and In Vivo T Cell ResponsesThe Journal of Immunology, 2011
- Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapsesProceedings of the National Academy of Sciences, 2006
- T Cell Receptor-Proximal Signals Are Sustained in Peripheral Microclusters and Terminated in the Central Supramolecular Activation ClusterImmunity, 2006
- High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigensJournal of Experimental Medicine, 2005
- Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: Manifestation of a dual activation thresholdProceedings of the National Academy of Sciences, 2003
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptorNature Biotechnology, 2002
- Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T LymphocytesJournal of Experimental Medicine, 1998